海特生物：公司有为个别欧盟国家提供中间体产品，但其营收占公司总营收比例小

Group 1 - The company has provided intermediate products to certain EU countries, but the revenue from these sales constitutes a small proportion of the company's total revenue [2] - The company has acknowledged the potential investment risks associated with its limited exposure to the EU market [2] - The inquiry was made by an investor on an interactive platform regarding the company's services in the EU region over the past two years [2]